New patents boost Myriad as legal battle continues
This article was originally published in Clinica
In a busy week for Myriad Genetics, the US company reinforced its diagnostic patent claims for the BRCA1 breast cancer gene and sent a further warning shot at rival OncorMed.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.